MODERN POSSIBILITIES OF THERAPY WITH INHIBITORS OF CONTROL POINTS IN METASTATIC UROTHELIAL CANCER

For a long time, chemotherapy remained the main treatment option for metastatic urothelial carcinoma (mUC). Over the past year, there have been revolutionary changes associated with the approval of five new drugs aimed at blocking the interaction between the surface protein of T-lymphocytes PD-1 and...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: R. A. Gafanov, S. V. Garmash, I. B. Kravtsov, S. V. Fastovets
Materyal Türü: Artigo
Dil:Russo
Baskı/Yayın Bilgisi: QUASAR, LLC 2018-03-01
Seri Bilgileri:Issledovaniâ i Praktika v Medicine
Konular:
bladder cancer
pd-1
pd-l1
immunotherapy
atezolizumab
nivolumab
pembrolizumab
avelumab
durvalumab
Online Erişim:https://www.rpmj.ru/rpmj/article/view/246
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller